We're using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.

By continuing to use our website without changing the settings, you're agreeing to our use of cookies.

Find out more
For more information, go to

Cancer risk after anti-TNF treatment

Issue 29 Synovium (Spring 2010)

Download this issue (opens in new window)(198.7 KB)

There is always the concern with powerful immunosuppressive treatments that the short-term benefit might be at the price of increased long-term risk of malignant disease. So it is comforting to read that in a Swedish study following 6366 patients with rheumatoid arthritis treated with the anti-TNF drugs infliximab, adalimumab and etanercept1 no increased risk of cancer was observed in 6 years of follow-up compared with patients on other therapies or not taking medication. Six years is not long in the timeline of a disease like rheumatoid arthritis and clearly much longer observation is needed, but this is encouraging information for patients.

Synovium archives

Browse previous issues of Synovium (all issues available as downloadable PDFs)

We're now

Versus Arthritis.

You're being taken through to our new website in order to finish your donation.

Thank you for your generosity.

For more information, go to
Arthritis Research UK fund research into the cause, treatment and cure of arthritis. You can support Arthritis Research UK by volunteering, donating or visiting our shops.